Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 14/20 | 0.73 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.66 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.64 |
| ▸ | MAOA | P21397 | 2/20 | 0.56 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29817726 | 1.00 | MAOB (0.73) | MAOBNR4A2PARP10MAOASCN9A | |
| SCHEMBL4425903 | 0.87 | MAOB (0.73) | MAOBNR4A2PARP10MAOASCN9A | |
| SCHEMBL3625818 | 0.86 | MAOB (0.73) | MAOBNR4A2PARP10MAOA | |
| SCHEMBL27521276 | 0.86 | MAOB (0.77) | MAOBNR4A2PARP10MAOA | |
| SCHEMBL992837 | 0.85 | MAOB (1.00) | MAOBNR4A2PARP10 | |
| SCHEMBL28488896 | 0.83 | MAOB (0.73) | MAOBNR4A2PARP10MAOASCN9A | |
| SCHEMBL993542 | 0.83 | MAOB (0.73) | MAOBNR4A2PARP10MAOASCN9A | |
| Hydrochloric Acid SCHEMBL21313331 | 0.83 | MAOB (1.00) | MAOBNR4A2PARP10 | |
| SCHEMBL4228330 | 0.83 | MAOB (0.73) | MAOBNR4A2PARP10MAOASCN9A | |
| SCHEMBL8276628 | 0.83 | MAOB (0.73) | MAOBNR4A2PARP10MAOASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115246781-B | Preparation method of sand-fenamide | 南京正大天晴制药有限公司 | 2024-03-29 | — | — | CN | claimed |
| CN-115246781-A | Preparation method of safinamide | 南京正大天晴制药有限公司 | 2022-10-28 | — | — | CN | claimed |
| CN-115246781-B | Preparation method of sand-fenamide | 南京正大天晴制药有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-112010818-B | Morpholinamide derivatives and uses thereof | 广东东阳光药业股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-114573491-B | Process for preparing pyrrolidine amide derivatives | 广东东阳光药业股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| EP-3762364-B1 | PYRROLIDINEAMIDE DERIVATIVES AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2023-08-23 | — | — | EP | disclosed |
| CN-110240557-B | Pyrrolidine amide derivatives and use thereof | 广东东阳光药业有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-115246781-A | Preparation method of safinamide | 南京正大天晴制药有限公司 | 2022-10-28 | — | — | CN | disclosed |
| CN-114573491-A | Process for preparing pyrrolidine amide derivatives | 广东东阳光药业有限公司 | 2022-06-03 | — | — | CN | disclosed |
| US-11225460-B2 | Pyrrolidineamide derivatives and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-01-18 | — | — | US | disclosed |
| US-20210053918-A1 | PYRROLIDINEAMIDE DERIVATIVES AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-02-25 | — | — | US | disclosed |
| WO-2014178083-A1 | AN IMPROVED SYNTHESIS OF ANTI-PARKINSON AGENT | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-11-06 | — | — | WO | disclosed |
| CN-100554244-C | New MAO-B inhibitor | HOFFMANN LA ROCHE (CH) | 2009-10-28 | — | — | CN | disclosed |
| EP-2093218-A1 | Arylalkyl substituted imidazolidinones | Fariello, Ruggero (IT) | 2009-08-26 | — | — | EP | disclosed |
| EP-1761480-B1 | MAO-B INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-02-18 | — | — | EP | disclosed |
| US-7253318-B2 | Benzyloxy derivatives as MAOB inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| CN-1972903-A | Novel MAO-B inhibitors | HOFFMANN LA ROCHE (CH) | 2007-05-30 | — | — | CN | disclosed |
| EP-1761480-A2 | NEW MAO-B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006000324-A2 | NEW MAO-B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-05 | — | — | WO | disclosed |
| US-20050288367-A1 | Benzyloxy derivatives as MAOB inhibitors | HOFFMAN-LA ROCHE INC. | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288367-A1 | Benzyloxy derivatives as MAOB inhibitors | MAOB, MAOA, COMT | MAOB 1/4885NR4A2 1668/4885PARP10 1329/4885 |
| US-11225460-B2 | Pyrrolidineamide derivatives and uses thereof | MAOB, MAOA, PARK7 | MAOB 1/4885NR4A2 3904/4885PARP10 158/4885 |
| US-20210053918-A1 | PYRROLIDINEAMIDE DERIVATIVES AND USES THEREOF | MAOB, MAOA, PARK7 | MAOB 1/4885NR4A2 3904/4885PARP10 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.